You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表现》中国抗体-B(03681.HK)开报7.3元 低上市价3.9%
阿思达克 11-12 09:24

中国抗体-B(03681.HK)暗盘低开7.9%报7元获承接,平收7.6元;该股首挂开报7.3元,较上市价7.6元,低3.9%,市场成交2,109万股。

中国抗体是专门研发、制造及商业化免疫性疾病疗法的香港生物制药公司,主要研制以单克隆抗体为基础的生物药。是次上市共发售1.82亿股,并已引入云南白药(000538.SZ)及瑞捷软件科技为基石投资者,合共认购约6,192万股(禁售期6个月);其中10%公开发售获近12倍超购,人人有份,股份以招股范围(7.6-9.6元)下限定价,料集资净额12.86亿元,主要用作研发和商业化其核心产品,以及建设苏州生产基地等。上市联席保荐人分别为中金公司及东方证券。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account